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To predict the public health impact on cervical disease by introducing human papillomavirus (HPV) vaccination in the United
Kingdom, we developed a mathematical model that can be used to reflect the impact of vaccination in different countries with
existing screening programmes. Its use is discussed in the context of the United Kingdom. The model was calibrated with published
data. The impact of vaccination on cervical cancer and deaths, precancerous lesions and screening outcomes were estimated for a
vaccinated cohort of 12-year-old girls, among which it is estimated that there would be a reduction of 66% in the prevalence of high-
grade precancerous lesions and a 76% reduction in cervical cancer deaths. Estimates for various other measures of the population
effects of vaccination are also presented. We concluded that it is feasible to forecast the potential effects of HPV vaccination in the
context of an existing national screening programme. Results suggest a sizable reduction in the incidence of cervical cancer and
related deaths. Areas for future research include investigation of the beneficial effects of HPV vaccination on infection transmission
and epidemic dynamics, as well as HPV-related neoplasms in other sites.
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Invasive cervical cancer (ICC) is the second most common cancer
in women worldwide, with approximately 470000 cases and
230000 deaths annually (Ferlay et al, 2002). The causal role of
human papillomavirus (HPV) in ICC is well established (Franco
et al, 1999a), with at least 13 types associated with ICC (Cogliano
et al, 2005). In the United Kingdom (UK), the cervical screening
programme has substantially reduced ICC deaths in women born
since 1950 (Peto et al, 2004a). However, ICC remains high for a
developed country, and cervical intraepithelial neoplasia (CIN) 3
and HPV incidence have increased in the last decade (Kitchener
et al, 2004; Peto et al, 2004b).
Globally, infection with HPV 16 and 18 accounts for more than
70% of ICC cases (Mun ˜oz et al., 2004). Two vaccines have been in
development and both show high levels of efficacy against these
types (Koutsky et al, 2002; Harper et al, 2004, 2006; Villa et al,
2005). A trial of one of these, a bi-valent HPV-16/18 vaccine,
reported efficacy of 95.1% (95% CI: 63.5–99.3%) against persistent
HPV-16/18 infection (Harper et al, 2004), and efficacy was
maintained over 4.5 years (Harper et al, 2006). Protection against
HPV types 31 (54.5% (95% CI: 11.5–77.7%)) and 45 (94.2% (95%
CI: 63.3–99.9%)) was also shown. Before vaccine implementation,
it is desirable to understand the long-term benefit using
mathematical modelling.
There is a long history of modelling in cervical cancer (Sherlaw-
Johnson et al, 1994, 1999; Jenkins et al, 1996; Karnon et al, 2004;
Sherlaw-Johnson and Philips, 2004), and studies in the US
(Kulasingham and Myers, 2003; Goldie et al, 2004; Taira et al,
2004) have found that HPV vaccination with screening is cost-
effective. There have been no published analyses of HPV
vaccination in the UK, where cervical disease and screening differs
from the US. We developed a generic model that could be used to
evaluate vaccine impact in different countries. In this paper, we
report the use of this model in the UK.
MATERIALS AND METHODS
Model overview
A Markov process model has been developed reflecting the natural
history of type-specific HPV infection and progression of cervical
lesions. The model is based on a set of mutually exclusive health
states corresponding to HPV infection, CIN lesions and ICC
(Figure 1). The aim of such modelling is to estimate the age-related
probabilities that an individual would be in one of the states. The
overall population effects of particular interventions are inferred
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birth cohort.
In computational terms, the model is composed of three
modules. The natural history module reflects the natural history
of disease without intervention. In parallel, the screening module
incorporates screening practice by adjusting the health state
probabilities corresponding to the proportion of women detected
and treated for disease. The vaccination module is structured to
allow the evaluation of the vaccination programme, in addition to
screening practice, by altering transition rates that reflect the
natural history of infection acquisition.
Natural history
The natural history of cervical disease is modelled as a sequence of
transitions, between mutually exclusive health states, occurring
every 6 months. The transitions occur with probabilities that are
age- and HPV type-specific. There are seven HPV categories in the
model (oncogenic HPV types (16, 18, 31, 45, 52, other oncogenic)
and low-risk HPV), where each category is subdivided into health
states corresponding to ‘normal’ (un-infected and disease-free),
four cervical disease states (HPV with no lesion, CIN 1, CIN 2 and
CIN 3) and four ICC states (Federation of Gynaecology and
Obstetrics (FIGO) Stage 1, Stage 2, Stage 3, Stage 4). The four FIGO
stages are subdivided according to whether cancer is diagnosed
(i.e., detected vs undetected cancer). Finally, there are additional
health states corresponding to cervical cancer and noncervical
cancer death.
It is assumed that in the absence of treatment, individuals can
progress or regress from states up to CIN 3 and thereafter may
progress to cervical cancer. Once in the cancer state, there is
assumed to be potential progression through successive cancer
states with no regression. Transition from the undetected to the
detected cancer state is defined by the stage-dependent probability
of developing symptoms. Further, these transitions are assumed to
depend on whether a woman takes part in screening, reflecting the
fact that cancer would be more likely to be detected with cytology.
If detected, it is assumed that all cancers are treated and
individuals remain in the same cancer state for their lifetime.
Movement to either cervical cancer or noncervical cancer death is
governed by cancer stage-related survival distribution, and
competing all-cause mortality.
In addition to being HPV type-specific, the risk of acquiring
infection and disease progression is age-specific, to account for
age-related differences in behaviour and biological susceptibility.
The potential role of natural immunity or age-related changes in
the cervix has not been explicitly modelled; however, the model
calibration process discussed below implicitly accounts for these
factors.
Screening
The screening module is based on a decision tree representing
options available in the UK after an abnormal cytology test,
including repeat cytology, diagnostic testing, more frequent
cytological follow-up and treatment of diagnosed lesions.
The ages at which women are screened, coverage rates and
observed screening practices are based on data reported from the
Cervical Screening Programme (Department of Health Bulletin,
2004). Where data were not available, recommendations from UK
Cancer
No HPV 
infection
HPV 
infection  CIN 1 CIN 2 CIN 3
Figure 1 Simplified structure of the human papillomavirus (HPV) and
cervical cancer natural history model. Model simulates the natural history of
HPV infection and cervical carcinogenesis while incorporating the under-
lying type-specific HPV distribution within each stage of cervical disease, by
use of a sequence of 6-month transitions among mutually exclusive health
states. The probabilities governing each of these transitions are conditional
on the type of HPV infection and age. Transitions to death owing to natural
causes can occur from any health state in the model.
Table 1 United Kingdom screening parameter model inputs
Screening patterns Value Reference
Start and stop age (years) 20–65 Department of Health Bulletin (2004)
Screening coverage
% Screened every 3 years (dependent on age) 33–73 Department of Health Bulletin (2004)
% Never screened in lifetime 7
Test characteristics
Cytology – sensitivity (specificity) 0.41–0.67 (0.966)
Probability of accurate biopsy CIN diagnosis 0.536 Cuzick et al (1995); Hopman et al (1998); Mitchell et al (1998)
Probability of biopsy underdiagnosed CIN lesion 0.2
Probability of biopsy overdiagnosed CIN lesion 0.263
Colposcopy – sensitivity (specificity) 0.96 (0.48)
Screening practices
Borderline dyskaryosis to triage cytology, (colposcopy) (%) 80 (20)
Mild dyskaryosis to triage cytology, (colposcopy) (%) 58 (42) Department of Health Bulletin (2004)
XModerate dyskaryosis to colposcopy (%) 100
Negative triage cytology to regular screening (repeat test) (%) 84 (16) Assumption/(NHS, 2004)
Positive triage cytology to colposcopy (%) 100
Negative colposcopy/biopsy to regular screening (%) 50
Negative colposcopy/biopsy to increased screening (%) 50
CIN 1 diagnosis to increased screening, (treatment) (%) 50 (50)
CIN 2 or 3 diagnoses to treatment (%) 100
CIN ¼ cervical intraepithelial neoplasia; Cytology sensitivity ¼ probability of abnormal cytology given true state is CIN 1+. The model includes probability of abnormal cytology
according to lesion type (i.e., CIN 1 to CIN 3) and therefore a range of values is provided; cytology specificity ¼ probability of normal cytology given true state is negative for
lesions.
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that women were compliant with screening, where either testing or
treatment was completed after abnormal diagnoses. After colpo-
scopy and biopsy, women are assumed to either revert to regular
screening again in 3 years, or increased screening within 1 year
depending on the diagnosis. Treatment of CIN lesions was
modelled using data from the National Health Service’s cervical
cancer screening guidelines (NHS, 2004) and the International
Agency for Research on Cancer (IARC) (2005) where it is reported
that the success rate of treating lesions is 90%. The sensitivity and
specificity of cytology was obtained from a UK study (Cuzick et al,
1995). Colposcopy and biopsy test characteristics were obtained
from a review of studies (Hopman et al, 1998; Mitchell et al, 1998).
Details of screening inputs are provided in Table 1.
Vaccination module
Vaccine efficacy is modelled by decreasing the probability of
acquiring HPV infection in the different HPV strata. Vaccine efficacy
could be varied over time, following vaccination, to incorporate
waning of efficacy. The model can accommodate any pattern of
vaccine waning and inclusion of booster shots. With a booster shot,
it is assumed that vaccine efficacy is restored to original levels.
Calibration
Calibration is the process of deriving estimates for quantities used
within the model as the basis for its predictions. Some of these,
such as screening coverage or stage-specific cancer survival, can be
taken from the literature. Although there may be some uncertainty
concerning such estimates, they at least provide a credible starting
point for analysis. Other quantities used within the model,
particularly some of the disease progression probabilities, are
more difficult to estimate as there is a dearth of published
literature on this topic. To estimate these, a process of calibration
was carried out, by allowing transition probabilities to vary within
established ranges, so that modelled predictions of key end points
for unvaccinated girls matched currently available epidemiological
data in the presence of screening. A comprehensive review of the
literature was completed to determine plausible transition prob-
ability ranges for calibration (sample references in Table 2).
The following end points were used for calibration:
(1) Age-specific HPV prevalence: data obtained from a popula-
tion-based study of 6462 girls in Manchester, between 1987
and 1993 (Peto et al, 2004b).
(2) HPV type distribution: Mid-point of values (UK studies) of
HPV-type distribution in normal cytology, low- and high-
Table 2 Six-month transition probabilities used in the United Kingdom model calibration
Variable Oncogenic HPV Nononcogenic HPV References
Lesion progression and regression
Normal to HPV o35 years 0.023–0.077 0.008–0.026 HPV acquisition and regression; Franco et al (1999b); Moscicki et al (2001);
Molano et al (2003); Schlecht et al (2003)
435 years 0.004–0.023 0.001–0.008
HPV to CIN 1 o35 years 0.045–0.050 0.037–0.042 Lesion progression and regression: Ho et al (1998); Melnikov et al (1998);
Holowaty et al (1999); Schlecht et al (2003); Cantor et al (2004)
435 years 0.05 0.042
CIN 1 to CIN 2 o35 years 0.014–0.278 0.007–0.017
435 years 0.035–0.315 0.017–0.020
CIN 2 to CIN 3 o35 years 0.100–0.185 0.100–0.185
435 years 0.185–0.200 0.185–0.200
HPV clearance o35 years 0.38 0.53
435 years 0.38 0.53
CIN 1 regression o35 years 0.340–0.440 0.380–0.480
435 years 0.31 0.32
CIN 2/3 regression o35 years 0.02 0.02
435 years 0.02 0.02
Progression to invasive cancer
CIN 3 to Cancer 0.002–0.017 0.008 Natural history of invasive cancer: De Rijke et al (2002); Goldie et al (2004)
Stage I
Progression to stage II 0.11 0.11
Probability of symptoms 0.075 0.075
Mortality 0.005–0.015 0.005–0.015
Stage II
Progression to stage III 0.12 0.12
Probability of symptoms 0.113 0.113
Mortality 0.015–0.040 0.015–0.040
Stage III
Progression to stage IV 0.12 0.12
Probability of symptoms 0.3 0.3
Mortality 0.050–0.090 0.050–0.090
Stage IV
Probability of symptoms 0.45 0.45
Mortality 0.070–0.120 0.070–0.120
Ranges are reported owing to probability variation in age and HPV type. References are provided that support the resulting transition probability values. CIN (cervical
intraepithelial neoplasia) 1 lesions can regress to HPV (human papillomavirus) infection or normal; CIN2/3 lesions can regress to HPV infection or normal. Details of the point
estimates from the calibrated model are available from the authors upon request.
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other oncogenic, low-risk) (Clifford et al, 2003a,b, 2005a,b).
(3) CIN prevalence: age-specific prevalence patterns of CIN 1 or
less (i.e., cytologically confirmed), CIN 2 and CIN 3 lesions
(i.e., histologically confirmed) reported in Manchester study
(Peto et al, 2004b). Overall CIN prevalence by lesion type
reported in Department of Health Bulletin (2004).
(4) Cancer incidence and mortality: age-specific rates (/100000)
from Office of National Statistics (2002a,b). Historical
incidence rates from IARC (Parkin, 1966).
Goodness-of-fit for HPV prevalence, cervical cancer incidence
and mortality were measured using an average percentage devi-
ation calculation (i.e., (observed – model predicted)/observed),
weighted by: (1) age-specific disease rates and (2) age-specific
number of cases expected. For CIN prevalence, goodness-of-fit
was calculated using overall rates.
Base-case analysis
We conducted an analysis to estimate the public health
benefits associated with HPV-16/18 vaccination in the setting of
cervical cancer screening in the UK, based on the conservative
assumption that current screening practice does not change. For
vaccinated and unvaccinated females, clinical events (i.e., HPV
infections, CIN lesions, cervical cancer cases and deaths) were
derived from the model for one birth cohort of girls from age of
vaccination until a maximum of 110 years. Rates of screening
events (abnormal cytology tests, biopsies, colposcopies, CIN
treatments) were also estimated. A vaccination coverage rate of
100% was assumed.
To examine the protection afforded by vaccination, a cohort of
376385 girls vaccinated at age 12 was modelled, representing
one annual age cohort in the UK (ONS, 2003). The following
assumptions were made based on published studies (Harper et al,
2004, 2006): (1) vaccination would reduce the probability of
acquiring HPV 16/18 by 95%; (2) vaccination offers protection
against other oncogenic types, reducing the probability of HPV 31
infection by 50%, and HPV 45 infection by 90%; (3) adolescents
would receive three doses of the vaccine and be fully immunized
after 1 year; and (4) vaccine efficacy does not wane over time.
Results from the extended phase of a clinical trial (Harper et al,
2006) indicate that waning is not expected in the short term (e.g.,
up to 10 years). In the longer term, such waning could in principle,
be countered by a booster.
Sensitivity analysis
Alternative assumptions about vaccine efficacy and waning,
vaccination coverage rate, vaccination age and HPV type distribu-
tion were explored using sensitivity analyses. Vaccine efficacy
for HPV types 16 and 18 was varied from 90 to 100%. As cross-
protection against types 31 and 45 has as yet only been
demonstrated for incident infection, alternative scenarios where
cross-protection was absent or waned were analysed. Waning of
immunity against types 31 and 45 was assumed to occur in a linear
manner to 0% of initial efficacy after 10 years, and was analysed
with and without a booster at 10 years after initial vaccination. In
the 4.5 years of follow-up in clinical trials, waning of efficacy
against HPV types 16 and 18 have not been observed; therefore,
it was assumed that waning would either not occur or would be
addressed by boosters. The impact of vaccinating older and
younger girls was also analysed (10 and 18 years). Also, as 100%
vaccination coverage is likely not achievable in practice in the
near term, an alternative vaccination coverage rate of 80% was
explored, based on the coverage actually achieved in recent
vaccination campaigns in adolescents (Wallace et al, 2004). Finally,
given the variability of literature that exists on HPV type
distribution in the UK, we also conducted an analysis that assumes
a lower HPV 16/18 type distribution (i.e., 72%) in ICC, reported for
Europe (vs 77% assumed for the UK).
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Figure 2 Comparison of model-predicted and observed data for HPV prevalence in the UK. (A) Age-specific HPV prevalence in the general population.
(B) HPV type distribution within low-grade squamous intraepithelial lesions (LSIL). (C) HPV-type distribution within high-grade squamous intraepithelial
lesions (HSIL)). (D) HPV-type distribution within cervical cancer. Oncogenic HPV types include all other oncogenic types except HPV types 16 and 18.
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Model calibration
Table 2 provides the transition probabilities that resulted from
calibration. Results showed that model outputs compared well with
UK data. The percentage deviations, calculated using age-specific
rates as weights, were 9.7, 13.8 and 17.8% for HPV prevalence,
cancer incidence and mortality, respectively. Results were similar
when using other weighting methods (data not shown). The
percentage deviation for overall CIN prevalence was 17.8%.
Specifically, age-specific HPV prevalence was matched well to
data from the Manchester study (Peto et al, 2004b), with a peak
prevalence age range of 15–19 years (Figure 2A). Model-predicted
CIN prevalence (CIN 1¼0.8%, CIN 2¼0.4%, CIN 3¼0.7%) was
comparable to data from the UK Screening Program (Department
of Health Bulletin, 2004) (CIN 1¼0.6%, CIN 2¼0.5%, CIN
3¼0.7%), with age-specific patterns similar to the Manchester
study. The model closely reproduced HPV type distribution within
normal cytology, cervical lesions and cancer, where values
generally remained within the range observed from studies across
the UK (Figure 2B, C, and D). The model predicted a crude average
cervical cancer incidence rate of 10.5 per 100000, compared with
the reported rate of 10.6 per 100000. Cervical cancer mortality also
showed good correspondence (Figure 3) (ONS, 2002a,b). Without
screening, the model predicted an age-specific pattern of cervical
cancer similar to historical rates (results not shown) (Parkin,
1966).
Public health impact of vaccination
Over the lifetime of the cohort of 12-year-olds, the model predicts
the occurrence of approximately 2636 cervical cancer cases and
1403 cancer deaths without vaccination, assuming that screening
practices remain constant. With vaccination, the forecast would be
as low as 632 cancer cases (76% reduction) and 335 cancer deaths
(76% reduction). Figure 4D describes the projected impact of
vaccination on the observed distribution of cervical cancer
incidence across ages.
Vaccination was also predicted to give a considerably high
reduction in the prevalence of high-grade lesions (i.e., CIN 2þCIN
3) across all ages (Figure 4C). In particular, vaccination was
estimated to lead to a 95% reduction in the prevalence of lesions
associated with HPV 16 and 18, consistent with what is assumed to
be the type-specific vaccine efficacy rate. When considering lesions
caused by all HPV types, the absolute prevalence of high-grade
lesions is predicted to reduce from 1.07 to 0.36% (66% reduction)
with vaccination. This estimated reduction of 66% falls within the
model-predicted percentage of high-grade lesions attributable to
HPV 16 and 18 and other oncogenic types (Figure 2).
It was also predicted that vaccination would have benefits in
relation to HPV prevalence and low-grade lesions (CIN 1),
although to a lesser extent. When considering only oncogenic
HPV, the estimated percentage reduction in HPV prevalence was
45% with vaccination (Figure 4A). For all HPV types within the
general population (oncogenicþlow-risk), the projected reduction
in HPV prevalence is lower at 35% (age-specific data not shown).
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specific cervical cancer incidence (A) and cervical cancer mortality (B).
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when considering CIN lesions caused by all HPV types, which is
comparable to the projected reduction of overall HPV prevalence
in the general population (Figure 4B).
As a consequence of the projected reductions in cervical disease
owing to vaccination, clinical benefit is anticipated from a
reduction in screening tests and treatments. Predicted numbers
of abnormal cytology tests, diagnostic tests and treatments for
precancerous lesions, occurring over the lifetime of a cohort of 12-
year-old girls, with and without vaccination are shown in Table 3.
With vaccination of the entire birth cohort, a reduction of close
to 75000 abnormal cytology tests is predicted. If the reduction in
follow-up cytology tests that are normal is included, a total
reduction of approximately 442000 cytology tests is predicted with
vaccination. The largest percentage reduction in screening and treat-
ment events is observed in treatment of CIN lesions, approaching
close to 43% reduction with 100% vaccination coverage.
Sensitivity analyses
We investigated the impact of varying assumptions concerning
vaccine efficacy and waning, vaccination coverage and age at
vaccination, assuming 100% vaccination coverage. Table 4 details
the results of these analyses for the more severe cervical outcomes.
Despite the range of sensitivity analyses conducted, model
predictions consistently suggested high efficacy of vaccination.
The absolute prevalence of high-grade lesions ranged from
0.33% (69% reduction) to 0.53% (50% reduction) with different
vaccination scenarios. Predictions for number of cases ranged
from 538 cancer cases (80% reduction) to 1032 cancer cases (61%
reduction) and cancer deaths from 287 deaths (80% reduction) to
549 deaths (61% reduction) for different vaccination scenarios. Of
all variables considered, results were most sensitive to age at
vaccination and the vaccination coverage rate.
DISCUSSION
The imminent global arrival of HPV vaccines with proven efficacy
against HPV types 16 and 18 (Koutsky et al, 2002; Harper et al,
2004, 2006; Villa et al, 2005) means that decisions on adoption will
soon need to be made across countries. These decisions are already
being made within the United States, with the recent approval of
Merck’s HPV vaccine (Gardasil
s). To facilitate such decisions, a
detailed model of the natural history of HPV infection and cervical
cancer was developed, capable of evaluating the long-term impact
of a type-specific HPV vaccine in different countries with varying
cervical cancer epidemiology and screening policies. The present
study gives an example of this adaptation to the specific situation
in the UK.
Calibration achieved a consistently close fit to HPV and CIN
prevalence, as well as ICC incidence and mortality for the UK.
Further, the model reflects the prevalence of HPV types within
different stages of cervical disease, including low- and high-grade
lesions, and ICC. Calibrating simultaneously across the spectrum
of cervical disease, which is not a new concept (see e.g. Goldie et al,
2004), provides a robust foundation for the evaluation of the long-
term impact of vaccination. Furthermore, we calibrated to data
Table 3 Impact of HPV 16/18 vaccine on abnormal cytology, diagnostic tests, and treated CIN lesions over the lifetime of a 12-year-old cohort in the
United Kingdom
Abnormal cytology test
a Colposcopy Biopsy Treated CIN lesions
0% vaccine coverage
311983 153245 99974 38437
100% vaccine coverage
237734 111504 67367 22123
Reduction owing to vaccine 74249 41741 32607 16314
% Reduction 23.8% 27.2% 32.6% 42.4%
aAbnormal cytology test includes those with borderline dyskaryosis or greater.
Table 4 The impact of alternative assumptions for vaccine efficacy,
waning, and vaccination age on selected cervical cancer outcomes in the
United Kingdom
CIN 2+CIN 3
prevalence
Cervical cancer
cases (n)
Cervical cancer
deaths (n)
No vaccine 1.07% 2636 1403
Base case
a
0.361% 632 335
% Reduction 66.3% 76.0% 76.1%
Scenario 1: Low efficacy (HPV 16/18)
0.390% 724 384
% Reduction 63.6% 72.5% 72.7%
Scenario 2: High efficacy (HPV 16/18)
0.331% 538 287
% Reduction 69.0% 79.6% 79.6%
Scenario 3: No cross protection
0.410% 710 375
% Reduction 61.7% 73.1% 73.3%
Scenario 4: Vaccination coverage (80%)
0.502% 1032 549
% Reduction 53.1% 60.8% 60.9%
Scenario 5: Lower age at vaccination (10 years)
0.361% 631 335
% Reduction 66.3% 76.0% 76.1%
Scenario 6: Higher age at vaccination (18 years)
0.535% 896 506
% Reduction 50.0% 66.0% 63.9%
Scenario 7: Vaccine waning (HPV 31, 45 types)
0.409% 709 375
% Reduction 61.8% 73.1% 73.3%
Scenario 8: Vaccine waning (HPV 31, 45 types)+Booster at 10 years
0.400% 698 368
% Reduction 62.7% 73.5% 73.8%
Scenario 9: Decreased HPV type distribution of 16/18 in cervical cancer
0.356% 749 397
% Reduction 66.7% 71.6% 71.7%
aBase case assumes 95% efficacy against 16 and 18 infection, 50% efficacy against HPV
31, 90% efficacy against HPV 45. No waning is assumed. Results are provided for
100% vaccine coverage.
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most recent epidemiological data in the UK. For some previous
models, calibration was conducted to match data in unscreened
women, which in the UK would have meant the use of older data
before screening was introduced. Both in previous models and
ours, calibration has been conducted using cross-sectional data
(Canfell et al, 2004; Goldie et al, 2004; Sherlaw-Johnson and
Philips, 2004; Taira et al, 2004). Ideally, we would have used
longitudinal data as we are modelling a single cohort over time, but
available UK data covered periods that were either too short or
extended before and after the introduction of screening, making
this impossible.
Perhaps the most striking model prediction is that 100%
vaccination coverage of a 12-year-old cohort of girls would lead
to a reduction of 66% in the prevalence of high-grade cervical
lesions and a 76% reduction in cervical cancer deaths. These
beneficial effects of vaccination are entirely plausible as they reflect
the prevalence of HPV 16/18 in high-grade lesions and cervical
cancer and the potential additional impact of prevention of HPV
45 and 31 infection (Clifford et al, 2003a,b). A comparable study of
vaccination against HPV 16 and 18 in the United States showed a
reduction in ICC of 65 with 100% vaccine coverage (Goldie et al,
2004). The higher predicted reduction in our study is likely due to
inclusion of efficacy against infection with HPV types 31 and 45, as
well as a higher proportion of ICC associated with HPV 16 and 18
reported in UK studies. As HPV type distribution within cervical
cancer varies geographically (Clifford et al, 2003b), it is expected
that the benefits of HPV vaccination will vary by region.
Results also predict that approximately one-quarter of abnormal
cytology tests and one-third of diagnostic tests and CIN treatments
would be avoided with vaccination. This has important implica-
tions for reducing both NHS costs and the distress associated
with positive tests (Bell et al., 1999). Furthermore, we have assumed
that introduction of a vaccine does not change current screening,
whereas in practice it may be possible to reduce the burden of
routine screening (Franco et al, 2006). Cost-effectiveness analyses
are needed to explore optimal screening practice in combination
with vaccination in the UK including the use of HPV testing in
screening, triage and follow-up.
Results were sensitive to an increase in vaccination age, with
projected benefits at 18 years reduced compared with 12 years.
This is due to the pre-existing level of persistent HPV infection and
related disease in the older adolescent and mature population and
vaccination is predicted to provide maximum benefit at age 12,
before sexual activity is initiated in most girls. Further, the
projected benefit of vaccination was lower when assuming an
80% vaccination coverage rate, a rate similar to that observed in
adolescent hepatitis B vaccination (Wallace et al, 2004). In this
scenario, however, we have not considered the beneficial effects of
herd immunity and would have thereby underestimated the full
potential benefit. Assuming no cross-protection against types 31
and 45 also reduced the projected benefit of vaccination. This is
important, as protection has only been demonstrated so far against
incident infection for these types. Furthermore, assuming that
protection against HPV types 31 and 45, though present, wanes to
zero within 10 years, results in little extra benefit compared with
assuming no cross protection, even if a booster is given after 10
years. However, this is an aggressively conservative waning profile
and data from larger phase III studies is needed to establish the
translation of protection against incident infection into prevention
of persistent infection and precancerous lesions and the durability
of protection for non-16/18 HPV types. Protection against all
oncogenic types is most important up to age 25 years, when the
risk of exposure to HPV is greatest, and it is possible that this
exposure may naturally boost and maintain protection. However,
boosters remain a possibility and their cost should be considered
in cost-effectiveness analyses of HPV-16/18 vaccination.
There are limitations to our estimates of the beneficial effects
of vaccination that should be considered. First, evidence suggests
that HPV prevalence rates have increased in the UK since 1990
(Kitchener et al, 2004), which could mean that the burden of
disease avoidable by vaccination is also increasing. We have
neither included these higher rates in the analysis nor have we
included the potential impact of vaccination on HPV-related
neoplasms in other sites, such as the vulva, vagina, anus, penis and
oropharynx. Second, through the effects of herd immunity, one
would expect a marked decrease in HPV prevalence rates among
males if girls were vaccinated. Thus, a secondary beneficial effect
of vaccination, which is not taken into account in our analysis,
would be to slow and perhaps even halt the growth of the HPV
epidemic. Estimating the magnitude of the latter effect is beyond
the scope of the present study. Third, the natural history of
multiple HPV infections was not explicitly modelled. Therefore,
the possibility that suppressing types 16 and 18 may allow the
prevalence of other oncogenic HPV types in CIN and ICC to
increase was not explored. Fourth, we have attempted to model
the disease in enough detail to generate estimates of sufficient
robustness to inform future health policy decisions. However,
owing to the limits imposed by model complexity and the available
data, as with previous modelling studies, it was not possible to
explicitly account for all of the known heterogeneity in the cervical
cancer disease process. Finally, as the model is calibrated to UK
data, caution should be exercised in applying these findings to
other regions with different screening practices and epidemiology.
In summary, mathematical models provide a means for extra-
polating results beyond clinical trials and exploring the long-term
impact of vaccination on outcomes. This analysis suggests that the
public health benefits of HPV 16/18 vaccination, within the context
of an effective screening programme, may be substantial in the UK,
with large reductions not only in cervical cancer incidence and
mortality, but also in the prevalence of precancerous lesions and
associated diagnostic tests and treatments.
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